Generic Name
OlanzapineTherapeutic Class: Drugs of Nervous System (Atypical neuroleptic drugs)
Indications:
(Schizophrenia, Prevention of Bipolar Disorder, Mania)
Presentation:
Olanzapine 5: Each tablet contains Olanzapine INN 5 mg.
Olanzapine 10: Each tablet contains Olanzapine INN 10 mg.
Description:
Olanzapine is a selective monoaminergic antagonist with high-affinity binding to Serotonin 5-HT, Dopamine, muscarinic, H1, and alpha receptors. It has a weak binding affinity to GABA-A, benzodiazepine, and beta-adrenergic receptors.
Dosage & Administration:
Schizophrenia, combination therapy for Mania, Bipolar Disorder:
The initial dose is 5-10 mg once daily. Daily dosage may subsequently be adjusted on the basis of individual clinical status within the range of 5-20 mg daily. Dosage is greater than 10 mg daily only after reassessment. The maximum dose is 20 mg daily.
Monotherapy for Mania:
Initially 15 mg once daily. Daily dosage may subsequently be adjusted on the basis of individual clinical status within the range of 5-20 mg daily. Dosage is greater than 15 mg only after reassessment. The maximum dose is 20 mg daily. Olanzapine can be given without regard to meals. Gradual tapering of the dose should be considered while discontinuing Olanzapine.
Side Effects:
Very common undesirable effects are somnolence and weight gain. Besides increased appetite, elevated glucose levels, elevated triglyceride levels, dizziness, akathisia, Parkinson's disease, dyskinesia, orthostatic hypotension, mild and transient anticholinergic effects including constipation and dry mouth, asthenia, edema, and photosensitivity reaction, etc. may be observed.
Precautions:
Precaution should be taken in case of impaired renal, hepatic, cardiovascular, cerebrovascular, and respiratory failure, prostatic hypertrophy, paralytic ileus, diabetes mellitus, Parkinson's disease, and pregnancy.
Use in Pregnancy & Lactation:
Pregnancy: There are no adequate and well-controlled studies in pregnant women.
Lactation: Olanzapine is excreted in breast milk. Patients should be advised not to breastfeed an infant if they are taking Olanzapine.
Interaction:
Olanzapine may antagonize the effects of levodopa and dopamine agonists. Drugs that induce CYP1A2 or glucoronyl transferase enzymes e.g, Omeprazole and Rifampicin, may increase Olanzapine clearance. Inhibitors of CYP1A2 may potentially inhibit Olanzapine elimination. Carbamazepine may increase the clearance of Olanzapine. Concomitant administration of activated charcoal reduces the oral bioavailability of Olanzapine by 50-60%. Caution should be taken when Olanzapine is administered with centrally acting drugs and alcohol.
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychoses where positive symptoms (e.g. delusions, hallucinations, disordered thinking, hostility, and suspiciousness) and/or negative symptoms (e.g. flattened affect, emotional and social withdrawal, poverty of speech) are prominent. Olanzapine is indicated for the treatment of acute manic or mixed episodes in bipolar disorder, with or without psychotic features and with or without a rapid-cycling course
Presentation:
Olanzapine 5: Each tablet contains Olanzapine INN 5 mg.
Olanzapine 10: Each tablet contains Olanzapine INN 10 mg.
Description:
Olanzapine is a selective monoaminergic antagonist with high-affinity binding to Serotonin 5-HT, Dopamine, muscarinic, H1, and alpha receptors. It has a weak binding affinity to GABA-A, benzodiazepine, and beta-adrenergic receptors.
Dosage & Administration:
Schizophrenia, combination therapy for Mania, Bipolar Disorder:
The initial dose is 5-10 mg once daily. Daily dosage may subsequently be adjusted on the basis of individual clinical status within the range of 5-20 mg daily. Dosage is greater than 10 mg daily only after reassessment. The maximum dose is 20 mg daily.
Monotherapy for Mania:
Initially 15 mg once daily. Daily dosage may subsequently be adjusted on the basis of individual clinical status within the range of 5-20 mg daily. Dosage is greater than 15 mg only after reassessment. The maximum dose is 20 mg daily. Olanzapine can be given without regard to meals. Gradual tapering of the dose should be considered while discontinuing Olanzapine.
Olanzapine can be given without regard to meals. Gradual tapering of the dose should be considered while discontinuing Olanzapine.
Side Effects:
Very common undesirable effects are somnolence and weight gain. Besides increased appetite, elevated glucose levels, elevated triglyceride levels, dizziness, akathisia, Parkinson's disease, dyskinesia, orthostatic hypotension, mild and transient anticholinergic effects including constipation and dry mouth, asthenia, edema, and photosensitivity reaction, etc. may be observed.
Precautions:
Precaution should be taken in case of impaired renal, hepatic, cardiovascular, cerebrovascular, and respiratory failure, prostatic hypertrophy, paralytic ileus, diabetes mellitus, Parkinson's disease, and pregnancy.
Use in Pregnancy & Lactation:
Pregnancy: There are no adequate and well-controlled studies in pregnant women.
Lactation: Olanzapine is excreted in breast milk. Patients should be advised not to breastfeed an infant if they are taking Olanzapine.
Interaction:
Olanzapine may antagonize the effects of levodopa and dopamine agonists. Drugs that induce CYP1A2 or glucoronyl transferase enzymes e.g, Omeprazole and Rifampicin, may increase Olanzapine clearance. Inhibitors of CYP1A2 may potentially inhibit Olanzapine elimination. Carbamazepine may increase the clearance of Olanzapine. Concomitant administration of activated charcoal reduces the oral bioavailability of Olanzapine by 50-60%. Caution should be taken when Olanzapine is administered with centrally acting drugs and alcohol.
Use in Special Populations:
Children: Olanzapine has not been studied in subjects under 18 years of age.
Elderly patients (age 65 and over): starting dose 5 mg/day
Patients with hepatic, renal impairment: starting dose 5 mg/day
Storage:
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Children: Olanzapine has not been studied in subjects under 18 years of age.
Elderly patients (age 65 and over): starting dose 5 mg/day
Patients with hepatic, renal impairment: starting dose 5 mg/day
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.